# **Supplementary Materials**

Levodopa-Reduced *Mucuna pruriens* Seed Extract shows Neuroprotective Effects against Parkinson's Disease in Murine Microglia and Human Neuroblastoma Cells, *Caenorhabditis elegans*, and *Drosophila melanogaster* 

Shelby L. Johnson<sup>2,3</sup>, Hyun Young Park<sup>4,5</sup>, Nicholas A. DaSilva<sup>2,3</sup>, Dhiraj A. Vattem<sup>4,5\*</sup>, Hang Ma<sup>1,2,3\*</sup>, Navindra P. Seeram<sup>2,3\*</sup>

<sup>1</sup>School of Biotechnology and Health Sciences, Wuyi University; International Healthcare Innovation Institute (Jiangmen), Jiangmen 529020, Guangdong, China; hang\_ma@uri.edu (H.M.)

<sup>2</sup>Bioactive Botanical Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA;

shelby\_johnson@uri.edu (S.L.J.); ndasilva@my.uri.edu (N.A.D.); nseeram@uri.edu (N.P.S.) <sup>3</sup>George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA

<sup>4</sup> Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA; vattem@ohio.edu (D.A.V.); parkh4@ohio.edu (H.Y.P.)

<sup>5</sup>School of Applied Health Sciences and Wellness, Ohio University, Athens, OH 45701, USA

## List of contents

HPLC-DAD analyses of <i>Mucuna pruriens</i> extracts
Morphological analysis
Figure S1. LC-ESI-MS/MS spectra for quantifications of L-dopa in <i>Mucuna pruriens</i> extracts4
Figure S2. HPLC-DAD chromatograms of <i>Mucuna pruriens</i> extracts
Figure S3. Effects of Mucuna pruriens extracts on the cell viability and LPS-induced NO production in
murine BV-2 microglia8
Figure S4. Morphology of BV-2 murine microglia treated with H2O2+MPE, H2O2+0.07% L-dopa, LPS+MPE,
and LPS+0.07% L-dopa9
Figure S5. Effects of MPE and 0.07% L-dopa on H <sub>2</sub> O <sub>2</sub> -induced toxicity in murine BV-2 microglia10
Figure S6. Effects of MPE and 0.07% L-dopa on LPS-induced NO production in murine BV-2 microglia 11
<b>Table S1.</b> Chemical constituents of <i>Mucuna pruriens</i> 12
References

#### HPLC-DAD analyses of Mucuna pruriens extracts

Chemical profiles of *Mucuna pruriens* extracts were performed using HPLC-DAD method. *M. pruriens* extracts including crude methanol, n-hexanes, ethyl acetate, butanol, and water extracts were prepared in 50% methanol/water (25 mg/mL). The column used was a Waters Sunfire® C18 column (250 mm × 4.6 mm i.d., 5  $\mu$ m; Milford, MA, USA) at room temperature. Solvent system consisted of 0.1% trifluoroacetic acid in water (A) and methanol (B). 0-25 min 97% A, 25-66 min 50% A, 66-81 min 5% A, 81-95 min 5% A, 95-96 min 97% A, and 96-110 min 97%A at a fow rate of 0.75 mL/min. Wavelength range for DAD detection was 220-520 nm and peaks were monitored at the wavelength of 250 nm. HPLC-DAD chromatograms are shown in Figure S2.

### Morphological analyses

Murine BV-2 microglia cells were stained with crystal violet staining post treatments to visualize morphological changes. Cells were fixed in 70% ethanol for 5 min, then stained with 0.5% crystal violet stain (Sigma-Aldrich Chemical Co.,St. Louis, MO, USA ) for 10 min. Cells were then washed in phosphate buffered saline, then imaged with EVOS ® FL Cell Imaging System (ThermoFisher Scientific, Waltham, MA, USA) in phase at 40X (Figure S4).

**Figure S1.** LC-ESI-MS/MS spectra of L-dopa (**A**) and L-dopa in the *Mucuna pruriens* extracts including crude methanol (**B**), n-hexanes (**C**), ethyl acetate (**D**), butanol (**E**), and water (**F**) extracts. The presence of L-dopa in the Mucuna extracts was identified as a peak with a retention time of 3.95 min with an ion transition of 198/152.



(B)



(A)



(C)







(E)

**Figure S2.** HPLC-DAD chromatograms of profiles of *Mucuna pruriens* extracts including crude methanol (**A**), n-hexanes (**B**), ethyl acetate (**C**), butanol (**D**), and water (**E**) extracts. Peaks were monitored at a wavelength of 250 nm.



**Figure S3.** Effects of *Mucuna pruriens* extracts including crude methanol, n-hexanes, ethyl acetate, butanol, and water extract (at concentration of 25 µg/mL) on the cell viability (**A**) and LPS-induced NO production in murine BV-2 microglia (**B**). Significance was reported by ANOVA followed with Dunnett multiple comparison testing, as compared to control  $p \le 0.001$  (####); as compared to toxic agent,  $p \le 0.05$  (\*),  $p \le 0.001$  (\*\*\*) and  $p \le 0.0001$  (\*\*\*\*).



**Figure S4.** Morphology of murine BV-2 microglia treated with vehicle (**A**), H<sub>2</sub>O<sub>2</sub> alone (**B**), H<sub>2</sub>O<sub>2</sub>+0.07% L-dopa (**C**), and H<sub>2</sub>O<sub>2</sub>+MPE (**D**); murine BV-2 microglia treated with vehicle (**E**), LPS alone (**F**), LPS+0.07% L-dopa (**G**), and LPS+MPE (**H**).



**Figure S5**. Effects of MPE and 0.07% L-dopa on H<sub>2</sub>O<sub>2</sub>-induced toxicity in murine BV-2 microglia. Significance was reported by ANOVA followed with Dunnett multiple comparison testing, as compared to control  $p \le 0.0001$  (####); as compared to toxic agent,  $p \le 0.05$  (\*).



**Figure S6.** Effects of MPE and 0.07% L-dopa on LPS-induced NO production in murine BV-2 microglia. Significance was reported by ANOVA followed with Dunnett multiple comparison testing, as compared to control  $p \le 0.0001$  (####); as compared to toxic agent,  $p \le 0.0001$  (\*\*\*\*).



Table S1. Chemical constituents of Mucuna pruriens.

Type of chemicals	chemicals	References
Polyphenols	Tannins, flavonoids (e.g. genistein and daidzein), gallic acid, phenolic acids	[1][2]
Saponins		[1][2]
Terpenoids		[1][2]
Alkaloids and amino acids	<ul> <li>β-Carboline, N,N-Dimethyl tryptamine, 5- hydroxytryptamine,</li> <li>bufotenine, tetrahydroisoquinoline, hydroisoquinoline,</li> <li>5-oxyindole- 3- alkylamine, 6- methoxyharman, arahidicacid,</li> <li>arginine, glutathione, indole- 3- alkylamine</li> </ul>	[3] [4]
Fatty acids	Linoleic acid, myristic acid, oleic acid, palmitic acid, vernolic acid, stearic acid	[5]
Carbohydrates	oligosaccharides (e.g. raffinose, stachyose, verbascose)	[6]

#### **References:**

- 1. Kasture, S.; Mohan, M.; Kasture, V. *Mucuna pruriens* seeds in treatment of Parkinson's disease: Pharmacological review. *Orient. Pharm. Exp. Med.* **2013**, *13*, 165–174, doi:10.1007/s13596-013-0126-2.
- 2. Sridhar, K. R.; Bhat, R. Agrobotanical, nutritional and bioactive potential of unconventional legume Mucuna. *Livest. Res. Rural Dev.* **2007**, *19*.
- 3. Damodaran, M.; Ramaswamy, R. Isolation of 1 -3:4-dihydroxyphenylalanine from the seeds of *Mucuna pruriens. Biochem. J.* **1937**, *31*, 2149–2152, doi:10.1042/bj0312149.
- 4. Misra, L.; Wagner, H. Lipid derivatives from *Mucuna pruriens* seeds. *Indian J. Chem. Sect. B Org. Med. Chem.* **2006**, 45, 801–804.
- 5. Natarajan, K.; Narayanan, N.; Ravichandran, N. Review on "Mucuna" The wonder plant. *Int. J. Pharm. Sci. Rev. Res.* **2012**, *17*, 86–93.
- Janardhanan, K.; Gurumoorthi, P.; Pugalenthi, M.; Nutritional nutritional potential of five accessions of a south Indian tribal pulse, *Mucuna pruriens* var utilis I. The effect of processing methods on the content of L-Dopa, phytic acid, and oligosaccharides. *Trop. Subtrop. Agroecosystems* 2003, 1, 141–152, doi:10.1016/j.theriogenology.2015.06.019.